Literature DB >> 33644115

Screening and Identification of Key Common and Specific Genes and Their Prognostic Roles in Different Molecular Subtypes of Breast Cancer.

Na Sun1, Pingping Gao1, Yanling Li1, Zexuan Yan2, Zaihui Peng1, Yi Zhang1, Fei Han3, Xiaowei Qi1.   

Abstract

Breast cancer is one of the most common cancers. Although the present molecular classification improves the treatment effect and prognosis of breast cancer, the heterogeneity of the molecular subtype remains very complex, and the applicability and effectiveness of treatment methods are still limited leading to poorer patient prognosis than expected. Further identification of more refined molecular typing based on gene expression profile will yield better understanding of the heterogeneity, improving treatment effects and prolonging prognosis of patients. Here, we downloaded the mRNA expression profiles and corresponding clinical data of patients with breast cancer from public databases and performed typical molecular typing using PAM50 (Prediction Analysis of Microarray 50) method. Comparative analyses were performed to screen the common and specific differentially expressed genes (DEGs) between cancer and corresponding para-cancerous tissues in each breast cancer subtype. The GO and KEGG analyses of the DEGs were performed to enrich the common and specific functional progress and signaling pathway involved in breast cancer subtypes. A total of 38 key common and specific DEGs were identified and selected based on the validated results, GO/KEGG enrichments, and the priority of expression, including four common DEGs and 34 specific DEGs in different subtypes. The prognostic value of these key common and specific DEGs was further analyzed to obtain useful potential markers in clinic. Finally, the potential roles and the specific prognostic values of the common and specific DEGs were speculated and summarized in total breast cancer and different subtype breast cancer based on the results of these analyses. The findings of our study provide the basis of more refined molecular typing of breast cancer, potential new therapeutic targets and prognostic markers for different breast cancer subtypes.
Copyright © 2021 Sun, Gao, Li, Yan, Peng, Zhang, Han and Qi.

Entities:  

Keywords:  biomarkers; breast cancer; diagnosis-breast cancer; molecular subtypes; prognosis

Year:  2021        PMID: 33644115      PMCID: PMC7905399          DOI: 10.3389/fmolb.2021.619110

Source DB:  PubMed          Journal:  Front Mol Biosci        ISSN: 2296-889X


  57 in total

1.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.

Authors:  Balazs Györffy; Andras Lanczky; Aron C Eklund; Carsten Denkert; Jan Budczies; Qiyuan Li; Zoltan Szallasi
Journal:  Breast Cancer Res Treat       Date:  2009-12-18       Impact factor: 4.872

2.  Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma.

Authors:  Natalia Teider; Deborah K Scott; Adrianne Neiss; S Dilhan Weeraratne; Vladimir M Amani; Yifei Wang; Victor E Marquez; Yoon-Jae Cho; Scott L Pomeroy
Journal:  Neuro Oncol       Date:  2010-09-16       Impact factor: 12.300

3.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study.

Authors:  Christos Sotiriou; Soek-Ying Neo; Lisa M McShane; Edward L Korn; Philip M Long; Amir Jazaeri; Philippe Martiat; Steve B Fox; Adrian L Harris; Edison T Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-13       Impact factor: 11.205

4.  Increased NEK2 in hepatocellular carcinoma promotes cancer progression and drug resistance by promoting PP1/Akt and Wnt activation.

Authors:  Sailan Wen; Yuwu Liu; Manyi Yang; Keda Yang; Jianghai Huang; Deyun Feng
Journal:  Oncol Rep       Date:  2016-08-09       Impact factor: 3.906

5.  Skeletal muscle-specific T-tubule protein STAC3 mediates voltage-induced Ca2+ release and contractility.

Authors:  Benjamin R Nelson; Fenfen Wu; Yun Liu; Douglas M Anderson; John McAnally; Weichun Lin; Stephen C Cannon; Rhonda Bassel-Duby; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

6.  Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer.

Authors:  Deena M A Gendoo; Natchar Ratanasirigulchai; Markus S Schröder; Laia Paré; Joel S Parker; Aleix Prat; Benjamin Haibe-Kains
Journal:  Bioinformatics       Date:  2015-11-24       Impact factor: 6.937

7.  High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097.

Authors:  Wei He; Leopoldo Luistro; Daisy Carvajal; Melissa Smith; Tom Nevins; Xuefeng Yin; James Cai; Brian Higgins; Kenneth Kolinsky; Christine Rizzo; Kathryn Packman; David Heimbrook; John F Boylan
Journal:  Mol Oncol       Date:  2011-01-21       Impact factor: 6.603

8.  The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene.

Authors:  Youguang Pu; Fangfang Zhao; Yinpeng Li; Mingda Cui; Haiyan Wang; Xianghui Meng; Shanbao Cai
Journal:  BMC Cancer       Date:  2017-01-10       Impact factor: 4.430

9.  The roles of AKR1C1 and AKR1C2 in ethyl-3,4-dihydroxybenzoate induced esophageal squamous cell carcinoma cell death.

Authors:  Wei Li; Guixue Hou; Dianrong Zhou; Xiaomin Lou; Yang Xu; Siqi Liu; Xiaohang Zhao
Journal:  Oncotarget       Date:  2016-04-19

10.  Osteoglycin (OGN) Inhibits Cell Proliferation and Invasiveness in Breast Cancer via PI3K/Akt/mTOR Signaling Pathway.

Authors:  Tao Xu; Rui Zhang; Menglu Dong; Zeyu Zhang; Hanning Li; Chenao Zhan; Xingrui Li
Journal:  Onco Targets Ther       Date:  2019-12-04       Impact factor: 4.147

View more
  1 in total

1.  Screening of Specific and Common Pathways in Breast Cancer Cell Lines MCF-7 and MDA-MB-231 Treated with Chlorophyllides Composites.

Authors:  Keng-Shiang Huang; Yi-Ting Wang; Omkar Byadgi; Ting-Yu Huang; Mi-Hsueh Tai; Jei-Fu Shaw; Chih-Hui Yang
Journal:  Molecules       Date:  2022-06-20       Impact factor: 4.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.